MedTrace Logo

Biosignatures of Latuda for Bipolar Depression

NCT02239094 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-12-12

Study results available
· View outcomes & findings →

Summary

The study proposes to conduct a pilot study of biological predictors of lurasidone response in bipolar depression.

Conditions

Interventions

DRUG

Lurasidone (Latuda)

Antipsychotic medication approved for use with Bipolar disorder

Sponsors & Collaborators

  • Sumitomo Pharma America, Inc.

    collaborator INDUSTRY

  • New York State Psychiatric Institute

    lead OTHER

Principal Investigators

  • Patrick J McGrath, MD · New York State Psychiatric Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02239094 on ClinicalTrials.gov